NeuroSense (NRSN) Therapeutics announced that the Brazilian Patent and Trademark Office has granted Brazilian Patent No. BR 112024007727-6, entitled “Compositions Comprising Ciprofloxacin and Celecoxib.” The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian patent (2022370513), provides protection for NeuroSense’s proprietary PrimeC composition in Brazil and extends patent coverage through October 2042, further strengthening the company’s global intellectual property estate and supporting the long-term development and potential commercialization of PrimeC in ALS, Alzheimer’s disease and additional neurodegenerative indications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status
- NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial
- NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens
- Neurosense Therapeutics Ltd. (NRSN) Q4 Earnings Cheat Sheet
- NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology